On the structural modification of 2-nitroimidazole-99mTc(CO)3 complex, a hypoxia marker, for improving in vivo pharmacokinetics

Nuclear Medicine and Biology

Volumn 39, Issue 8, 2012, Pages 1236-1242

  Mallia, Madhava B ^a   Kumar, Chandan ^a   Mathur, Anupam ^b   Sarma, H D ^a   Banerjee, Sharmila ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

^b Medical and Biological Products Program   (India)

Author keywords

2 nitroimidazole; Ether linkage; Fibrosarcoma; Hypoxia; Technetium 99m; Tricarbonyl core

Indexed keywords

2 NITROIMIDAZOLE IMINODIACETIC ACID TRICARBONYL COMPLEX TC 99M; 2 NITROIMIDAZOLE TRICARBONYL COMPLEX TC 99M; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RETENTION; DRUG STRUCTURE; DRUG SYNTHESIS; FIBROSARCOMA; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; LIVER CLEARANCE; MOUSE; NONHUMAN;

ANIMALS; BIOLOGICAL MARKERS; CELL HYPOXIA; FIBROSARCOMA; IMIDAZOLES; LIGANDS; MICE; ORGANOTECHNETIUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84867854951     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.07.005     Document Type: Article

References (34)

1. Mees G., Dierckx R., Vangestel C., Van de Wiele C. Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 2009, 36(10):1674-1686.
2. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996, 56(19):4509-4515.
3. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., Chapman W., Levin W., Manchul L., Keane T.J., Hill R.P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 1998, 48(2):149-156.
4. Nordsmark M., Overgaard M., Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996, 41(1):31-39.
5. Brizel D.M., Sibley G.S., Prosnitz L.R., Scher R.L., Dewhirst M.W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997, 38(2):285-289.
6. Nordsmark M., Bentzen S.M., Rudat V., Brizel D., Lartigau E., Stadler P., Becker A., Adam M., Molls M., Dunst J., Terris D.J., Overgaard J. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77(1):18-24.
7. Duffy J.P., Eibl G., Reber H.A., Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2003, 2:12.
8. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996, 56(5):941-943.
9. McKeown S.R., Cowen R.L., Williams K.J. Bioreductive drugs: from concept to clinic. Clin Oncol (R Coll Radiol) 2007, 19(6):427-442.
10. Olive P.L., Banáth J.P., Aquino-Parsons C. Measuring hypoxia in solid tumours-is there a gold standard?. Acta Oncol 2001, 40(8):917-923.
11. Vaupel P., Höckel M., Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007, 9(8):1221-1235.
12. Graves E.E., Giaccia A.J. Imaging tumoral hypoxia: oxygen concentrations and beyond. Oncology 2007, 21(3):368-376.
13. Evans S.M., Joiner B., Jenkins W.T., Laughlin K.M., Lord E.M., Koch C.J. Identification of hypoxia in cells and tissues of epigastric 9L rat glioma using EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide]. Br J Cancer 1995, 72(4):875-882.
14. Varia M.A., Calkins-Adams D.P., Rinker L.H., Kennedy A.S., Novotny D.B., Fowler W.C., Raleigh J.A. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. Gynecol Oncol 1998, 71(2):270-277.
15. Zhao D., Constantinescu A., Jiang L., Hahn E.W., Mason R.P. Prognostic radiology: quantitative assessment of tumor oxygen dynamics by MRI. Am J Clin Oncol 2001, 24(5):462-466.
16. Zhao D., Constantinescu A., Hahn E.W., Mason R.P. Differential oxygen dynamics in two diverse Dunning prostate R3327 rat tumor sublines (MAT-Lu and HI) with respect to growth and respiratory challenge. Int J Radiat Oncol Biol Phys 2002, 53(3):744-756.
17. Zhao D., Ran S., Constantinescu A., Hahn E.W., Mason R.P. Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia 2003, 5(4):308-318.
18. Zhao D., Constantinescu A., Chang C.H., Hahn E.W., Mason R.P. Correlation of tumor oxygen dynamics with radiation response of the dunning prostate R3327-HI tumor. Radiat Res 2003, 159(5):621-631.
19. Krohn K.A., Link J.M., Mason R.P. Molecular imaging of hypoxia. J Nucl Med 2008, 49(SUPPL 2):129S-148S.
20. Lee S.T., Scott A.M. Hypoxia positron emission tomography imaging with 18f-fluoromisonidazole. Semin Nucl Med 2007, 37(6):451-461.
21. Piert M., Machulla H.J., Picchio M., Reischl G., Ziegler S., Kumar P., Wester H.J., Beck R., McEwan A.J., Wiebe L.I., Schwaiger M. Hypoxia-specific tumor imaging with 18F-fluoroazomycin arabinoside. J Nucl Med 2005, 46(1):106-113.
22. Reischl G., Dorow D.S., Cullinane C., Katsifis A., Roselt P., Binns D., Hicks R.J. Imaging of tumor hypoxia with [124I]IAZA in comparison with [18F]FMISO and [18F]FAZA-first small animal PET results. J Pharm Pharm Sci 2007, 10(2):203-211.
23. Yang D.J., Wallace S., Cherif A., Li C., Gretzer M.B., Kim E.E., Podoloff D.A. Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia. Radiology 1995, 194(3):795-800.
24. Ballinger J.R. Imaging hypoxia in tumors. Semin Nucl Med 2001, 31(4):321-329.
25. Nunn A., Linder K., Strauss H.W. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med 1995, 22(3):265-280.
26. Mallia M.B., Banerjee S., Venkatesh M. Technetium-99m labelled molecules for hypoxia imaging. Technetium-99m radiopharmaceuticals: status and trends 2009, 295-316. IAEA, Vienna.
27. Wardman P. Reduction potentials of one electron couples involving free radicals in aqueous solutions. J Phys Chem Ref Data 1989, 18(4):1637-1755.
28. 3 complexes to target hypoxic tumors. J Label Compd Radiopharm 2010, 53(8):535-542.
29. Savi A., Gerundini P., Zoli P., Maffioli L., Compierchio A., Colombo F., Matarrese M., Deutsch E. Biodistribution of Tc-99m methoxy-isobutyl-isonitrile (MIBI) in humans. Eur J Nucl Med 1989, 15(9):597-600.
30. Kelly J.D., Forster A.M., Higley B., Archer C.M., Booker F.S., Canning L.R., Chiu K.W., Edwards B., Gill H.K., McPartlin M., et al. Technetium-99m-tetrofosmin as a new radiopharmaceutical for myocardial perfusion imaging. J Nucl Med 1993, 34(2):222-227.
31. Liu S., He Z., Hsieh W.Y., Kim Y.S. Evaluation of novel cationic (99m)Tc-nitrido complexes as radiopharmaceuticals for heart imaging: improving liver clearance with crown ether groups. Nucl Med Biol 2006, 33(3):419-432.
32. 6]. Polyhedron 1996, 15:1079-1089.
33. 99mTc). Inorg Chim Acta 2006, 359:2128-2134.
34. Troutner D.E., Volkert W.A., Hoffman T.J., Holmes R.A. A neutral lipophilic complex of 99mTc with a multidentate amine oxime. Int J Appl Radiat Isot 1984, 35(6):467-470.